| Table 2. Results of ovarian stimulation per stimulation cycle following ICSI | |||
| Group 1 r-hFSH:r-hLH 2:1 (n=50) |
Group 2 HP-hMG (n=47) |
Difference Group 1- Group2 (95% CI) |
|
|---|---|---|---|
| Oocytes inseminated | 11.3 (1.4) 7-13 |
11.6 (1.9) 6-14 |
-0.3 (-1.0 to 0.4 ) |
| Semen donor (heterologous/homologous), n (%) | 14/36 (28.0) |
13/34 (27.7) |
0.3 (-23.5 to 22.2) |
| 2PN embryos | 8.3 (2.3) 3-13 |
8.5 (2.0) 4-12 |
-0.20 (-1.1 to 0.7) |
| Total blastocysts | 6.1 (6.1) 2-11 |
4.8 (2.5) 0-10 |
1.4 (0.3 to 2.4) |
| Number of blastocysts with Good morphology |
3.4 (2.0) 0-9 |
2.5 (2.0) 0-7 |
0.9 (0.6 to 1.7)† |
| Proportion of blastocysts with Good morphology |
55.3 | 47.1 | 8.2 (-20.0 to 25.6) |
| Number of blastocysts with Fair morphology |
2.0 (1.5) 0-5 |
1.6 (1.3) 0-4 |
0.4 (-0.18 to 0.1) |
| Number of blastocysts with Poor morphology |
0.8 (1.0) 0-4 |
0.9 (0.9) 0-3 |
-0.04 (-0.4 to 0.3) |
Results are presented as mean (SD), min-max, unless stated otherwise. Some participants underwent more than one stimulation cycle; therefore, the number of cycles is higher than the number of donors.
*Blastocyst morphology assessed according to the Gardner and SART grading systems.
†Kruskal-Wallis test p value = 0.0359.
AMA, advanced maternal age. BMI, body mass index. HP-hMG, highly purified human menopausal gonadotropin. POR, poor ovarian reserve. r-hFSH, recombinant human follicle stimulating hormone, r-hLH, recombinant human luteinising hormone.